Overview Dividends

(ARVN) Arvinas - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04335A1051

PROTAC, Cancer, Breast, Prostate, Neurodegenerative

ARVN EPS (Earnings per Share)

EPS Growth (3Y CAGR): 38.53%
EPS Trend (3Y Correlation): 69.1%

ARVN Revenue

Revenue Growth (3Y CAGR): -10.40%
Revenue Trend (3Y Correlation): 13.7%

Description: ARVN Arvinas October 23, 2025

Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotech that pioneers proteolysis-targeting chimeras (PROTACs) – engineered molecules that recruit the body’s ubiquitin-proteasome system to selectively destroy disease-causing proteins.

Its lead pipeline consists of three oral PROTAC candidates in Phase 3: Bavdegalutamide and ARV-766 for metastatic castration-resistant prostate cancer, and ARV-471 for estrogen-receptor-positive/HER2-negative breast cancer. Earlier-stage programs include ARV-393 (BCL6 degrader, Phase 1), ARV-102 (neurodegeneration, Phase 1) and a pre-clinical KRAS G12D degrader for pancreatic and colorectal cancers.

As of the latest Q2 2024 filing, Arvinas reported cash and equivalents of roughly $210 million, giving it an estimated 12-month runway at its current burn rate of $18-20 million per quarter. The company’s revenue remains nil, and it posted a net loss of $115 million for the year, reflecting heavy R&D spend-typical for a firm with multiple late-stage trials.

The PROTAC modality is gaining traction industry-wide, with the global market projected to exceed $7 billion by 2030, driven by unmet needs in oncology and the promise of targeting “undruggable” proteins. Strategic collaborations with Pfizer, Genentech, Roche, Carrick Therapeutics, and Bayer provide both validation of the platform and potential milestone upside.

For a deeper, data-driven view of ARVN’s valuation dynamics, you may find ValueRay’s analyst toolkit worth exploring.

ARVN Stock Overview

Market Cap in USD	744m
Sub-Industry	Pharmaceuticals
IPO / Inception	2018-09-27

ARVN Stock Ratings

Growth Rating	-78.6%
Fundamental	40.4%
Dividend Rating	-
Return 12m vs S&P 500	-70.1%
Analyst Rating	4.05 of 5

ARVN Dividends

Currently no dividends paid

ARVN Growth Ratios

Growth Correlation 3m	88.6%
Growth Correlation 12m	-59.3%
Growth Correlation 5y	-84.5%
CAGR 5y	-38.59%
CAGR/Max DD 3y (Calmar Ratio)	-0.43
CAGR/Mean DD 3y (Pain Ratio)	-0.67
Sharpe Ratio 12m	-0.05
Alpha	-106.71
Beta	2.395
Volatility	60.44%
Current Volume	2287.9k
Average Volume 20d	2241.1k
Stop Loss	9 (-6%)
Signal	-0.40

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-72.6m TTM) > 0 and > 6% of Revenue (6% = 22.4m TTM)

FCFTA -0.44 (>2.0%) and ΔFCFTA -26.91pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 196.3% (prev 974.8%; Δ -778.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.44 (>3.0%) and CFO -396.4m <= Net Income -72.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 5.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (73.0m) change vs 12m ago 1.53% (target <= -2.0% for YES)

Gross Margin 99.57% (prev 92.71%; Δ 6.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.06% (prev 7.29%; Δ 26.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.50 (EBITDA TTM -115.7m / Interest Expense TTM -48.5m) >= 6 (WARN >= 3)

Altman Z'' -6.16

(A) 0.80 = (Total Current Assets 889.5m - Total Current Liabilities 157.8m) / Total Assets 909.3m

(B) -1.66 = Retained Earnings (Balance) -1.51b / Total Assets 909.3m

warn (B) unusual magnitude: -1.66 — check mapping/units

(D) -5.03 = Book Value of Equity -1.51b / Total Liabilities 300.0m

Total Rating: -6.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.38

1. Piotroski 1.0pt = -4.0

2. FCF Yield data missing

3. FCF Margin data missing

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda 0.91 = 1.89

6. ROIC - WACC (= -34.54)% = -12.50

7. RoE -12.01% = -2.00

8. Rev. Trend 13.74% = 1.03

9. EPS Trend 69.14% = 3.46

What is the price of ARVN shares?

As of November 06, 2025, the stock is trading at USD 9.57 with a total of 2,287,931 shares traded.
Over the past week, the price has changed by -0.21%, over one month by -0.52%, over three months by +25.76% and over the past year by -64.42%.

Is Arvinas a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Arvinas (NASDAQ:ARVN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.38 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARVN is around 6.16 USD . This means that ARVN is currently overvalued and has a potential downside of -35.63%.

Is ARVN a buy, sell or hold?

Arvinas has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ARVN.

Strong Buy: 9
Buy: 4
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ARVN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	18	88.1%
Analysts Target Price	18	88.1%
ValueRay Target Price	7.3	-24.2%

ARVN Fundamental Data Overview November 02, 2025

Market Cap USD = 744.5m (744.5m USD * 1.0 USD.USD)
P/E Forward = 17.6991
P/S = 1.9969
P/B = 1.117
Beta = 2.395
Revenue TTM = 372.8m USD
EBIT TTM = -121.1m USD
EBITDA TTM = -115.7m USD
Long Term Debt = 500.0k USD (from longTermDebt, last quarter)
Short Term Debt = 3.60m USD (from shortTermDebt, last quarter)
Debt = 9.90m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -105.0m USD (from netDebt column, last quarter)
Enterprise Value = -106.8m USD (744.5m + Debt 9.90m - CCE 861.2m)
Interest Coverage Ratio = -2.50 (Ebit TTM -121.1m / Interest Expense TTM -48.5m)
FCF Yield = 373.4% (FCF TTM -399.0m / Enterprise Value -106.8m)
FCF Margin = -107.0% (FCF TTM -399.0m / Revenue TTM 372.8m)
Net Margin = -19.47% (Net Income TTM -72.6m / Revenue TTM 372.8m)
Gross Margin = 99.57% ((Revenue TTM 372.8m - Cost of Revenue TTM 1.60m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = -0.12 (set to none) (Enterprise Value -106.8m / Total Assets 909.3m)
Interest Expense / Debt = 71.72% (Interest Expense 7.10m / Debt 9.90m)
Taxrate = 0.65% (-400.0k / -61.6m)
NOPAT = -120.3m (EBIT -121.1m * (1 - 0.65%)) [loss with tax shield]
Current Ratio = 5.64 (Total Current Assets 889.5m / Total Current Liabilities 157.8m)
Debt / Equity = 0.02 (Debt 9.90m / totalStockholderEquity, last quarter 609.3m)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -105.0m / EBITDA -115.7m)
Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -105.0m / FCF TTM -399.0m)
Total Stockholder Equity = 604.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.98% (Net Income -72.6m / Total Assets 909.3m)
RoE = -12.01% (Net Income TTM -72.6m / Total Stockholder Equity 604.3m)
RoCE = -20.02% (EBIT -121.1m / Capital Employed (Equity 604.3m + L.T.Debt 500.0k))
RoIC = -19.89% (negative operating profit) (NOPAT -120.3m / Invested Capital 604.8m)
WACC = 14.65% (E(744.5m)/V(754.4m) * Re(14.84%) + (debt cost/tax rate unavailable))
Discount Rate = 14.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.55%
Fair Price DCF = unknown (Cash Flow -399.0m)
EPS Correlation: 69.14 | EPS CAGR: 38.53% | SUE: 0.83 | # QB: 0
Revenue Correlation: 13.74 | Revenue CAGR: -10.40% | SUE: -0.18 | # QB: 0

Additional Sources for ARVN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle